Neglected Tropical Disease Treatment Market Size & Share 2025 – 2034

Neglected Tropical Disease Treatment Market Size

The global neglected tropical disease treatment market size was valued at USD 3.7 billion in 2024. The market size is estimated to grow from USD 3.9 billion in 2025 to USD 5.8 billion in 2034, growing at a CAGR of 4.6% from 2025 to 2034. Neglected tropical diseases (NTDs) treatment refers to the various therapy techniques involved in the prevention, control, and cure of 20 communicable diseases that the World Health Organization recognizes as NTDs.

These diseases mainly affect underprivileged people living in tropical and sub-tropical areas, where healthcare services are limited. The treatment of NTDs commonly consists of mass drug administration programs, targeted efforts, and multi-faceted control strategies aimed at controlling the burden of diseases.
 

The neglected tropical disease (NTD) treatment market is growing significantly due to increasing NTD cases. Diseases such as dengue, leprosy, and Chagas disease remain major threat to global health. For instance, in 2023, the World Health Organization (WHO) reported that 184 countries, territories, and areas reported 182,815 new cases of leprosy. Amongst these, 39.8% (72,845) of the cases were female and 5.6% (10,322) were children.
 

Additionally, 9,729 new grade 2 disability (G2D) cases were detected, of which 2.7% were children. The highest rates of new case detection occur in countries within the WHO African and South-East Asia regions. Similarly, soil-transmitted helminthiases affect almost 1.5 billion people worldwide, causing chronic anemia, malnutrition, and underdevelopment of children in poor countries. The ongoing burden of these illnesses is expected to increase the demand for better treatment access in affected regions.
 

Additionally, government programs and international collaborations are actively addressing the challenges in NTD treatments. For example, the WHO has created the NTD Roadmap 2021-2030, which aims to reduce the number of people needing NTD treatments by 90 percent by 2030. The program will also work to eliminate diseases like yaws and trachoma by 2030.
 

Neglected Tropical Disease Treatment Market Trends

• There are growing investments in investigational vaccines for Chagas disease and the development of biologics and antiparasitic drugs, which is expected to reach USD 37 billion by 2032.
   
• For instance, a therapeutic vaccine containing Trypanosoma cruzi, which is the protozoan parasite responsible for Chagas disease, is in the development stage and with the preclinical results it will enhance disease management.
   
• Furthermore, the newly gained attention towards neglected tropical diseases (NTDs) is a major driver of the NTD treatment market as it helps in getting funding and research activities. The public and institutional awareness regarding these diseases which impact hundreds of millions of people is helping accelerate the efforts to create more effective treatment solutions.
   
• For example, WHO and GAVI are stepping up their work on NTDs which will lead to more funding for vaccines and other therapeutic interventions. This level of attention is anticipated to fast-track the response to control these diseases in affected areas.
   
• In addition, the implementation of open-source projects has made it easier to share drug information and increased research on NTDs. This collaborative model has led to new drug discoveries and shows promise for simpler drug development paths. For instance, GSK is a founding member of an open innovation platform dedicated to advancing NTD and malaria treatment. GSK contributes to the discovery and development of new drugs by sharing therapeutic research data and working with international partners, which strengthens the capability and accessibility of treatment.
   

Neglected Tropical Disease Treatment Market Analysis

Based on disease type, the market is segmented into dengue, rabies, trachoma, Buruli ulcer, yaws, leprosy, Chagas disease, human African trypanosomiasis (sleeping sickness), leishmaniases, soil-transmitted helminthiases, and other disease types. The market was valued at USD 3.7 billion in 2024. The dengue segment accounted for 15% of market share in 2024.
 

• The increasing rate of dengue infections and deaths is a serious concern for public health. The WHO has estimated the prevalence of the disease at around 390 million people, with over 20,000 lives lost each year in tropical and subtropical areas. Also, the incidence of the disease has increased significantly, with a 30-fold increase in the past 50 years, which has become a public health concern.
   
• Additionally, the approval of the vaccine Dengvaxia in several countries has increased activity in the endemic areas of the market.
   
• Thus, the increasing incidence and severity of dengue, along with the development of its vaccines, are creating a need for effective treatment options and prevention strategies.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on treatment type, the neglected tropical disease treatment market is segmented into drugs and vaccines. The drugs segment dominated the market by accounting for a market value of USD 2.7 billion in 2024. The drugs segment is further bifurcated into anti-parasite, antifungal, antibiotics and other drugs.
 

• The dominant and essential strategy used to treat neglected tropical diseases (NTDs) is through administering drugs.
   
• For instance, the WHO reported in 2021 that over 1 billion people treated annually for NTDs over the past five years through intensive campaign-based treatment programs conducted with numerous organizations and stakeholders.
   
• Such efforts are significant in reducing the prevalence of these diseases and highlight the role of drug-based approaches serve in combating global NTD strategies.
   
• Also, ongoing investments by pharmaceutical companies are a major factor for the sustained dominance of this segment.
   
• For instance, in June 2022, the World Health Organization recognized GSK for renewing its pledge to donate the drug albendazole until lymphatic filariasis is eliminated as a global public health issue. Furthermore, GSK committed to donate 200 million tablets every year till 2025 for soil transmitted helminthiases and 5 million tablets per year till 2025 for cystic echinococcosis.
   

Based on route of administration, the neglected tropical disease treatment market is bifurcated into oral and injectable segments. The oral segment accounted for the largest market share of 56.8% in 2024.
 

• Oral administration is the simplest and most feasible treatment method, making it useful especially for diseases such as leprosy, where multi-drug therapy is supplied in blister packs for the patients’ convenience.
   
• Moreover, trachoma prevention programs make use of mass treatment with oral drug - azithromycin to prevent blindness, benefiting millions of people in endemic areas every year.
   
• This signifies that oral treatment's practicality and efficiency fosters greater patient compliance through better treatment adherence, which is vital for controlling and eliminating NTDs in endemic areas, thereby advancing the market even more.
   

Based on distribution channel, the neglected tropical disease treatment market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies segments. The hospital pharmacies segment accounted for the largest market share of 57.3% in 2024.
 

• Hospital pharmacies are vital in offering treatments to NTDs such as advanced human African trypanosomiasis (HAT) because of the required monitoring and individualized treatment plans designed specifically for the patient due to safety concerns.
   
• Hospital pharmacies also ensure better patient outcomes and lower the risk of complications with NTD treatments through proper drug administration and complex therapy management.
   
• Furthermore, hospital pharmacies play an active role in controlling medications for more advanced cases as they promptly provide necessary drugs to patients in underserved areas with limited healthcare services.
   
• Therefore, hospital pharmacies enhance the care given to the patients suffering from NTDs and help control and eradicate these diseases in endemic regions.
   

North America: The U.S. neglected tropical disease treatment market was valued at USD 1.33 billion and is projected to maintain a strong position, reaching USD 2.1 billion by 2034.
 

• The increasing burden of NTDs in the country emphasizes the need for treatment interventions to address these diseases.
   
• For example, there is an estimation, based on the statistics provided by CDC, 300,000 people in the US have been suffering from Chagas disease, along with more than 1,800 new cases of leprosy coming forward each year which is a case for deeper focus.
   
• Furthermore, government funding and philanthropic initiatives, such as partnerships between the NIH and global health organizations enable patients to access better treatment.
   

Europe: The UK neglected tropical disease treatment market is expected to experience steady growth from 2025 to 2034.
 

• The presence of imported NTD cases in the UK underscores the need for more enhanced surveillance and preventive actions.
   
• The United Kingdom reported 1,012 cases of imported malaria in 2021. This included 954 cases in England, 29 in Scotland, 21 in Wales, and 8 in Northern Ireland. Compared to the previous year, this was an increase of 79% (564 cases), but it was 29% lower than the yearly average of 1,425 cases recorded between 2012 and 2019.
   

• The UK is taking important steps to address global NTDs by funding research and disease elimination programs, showing its efforts to deal with these diseases beyond its borders.
   

• For instance, the UK has been a major donor to the Global Fund, contributing USD ~5.7 billion since 2002, with a pledge of USD ~1.3 billion for the seventh replenishment. This funding supports efforts to combat infectious diseases, including those classified as NTDs, through prevention, treatment, and research initiatives.
   

Asia Pacific: Japan neglected tropical disease treatment market is anticipated to witness lucrative growth between 2025 - 2034.
 

• There is a steady growth in investment focused on the treatment of neglected tropical diseases (NTDs), and concurrently increasing funding is being directed into the development of their diagnostics and therapeutic innovations.
   
• For instance, the Japan-based public-private partnership (PPP) Global Health Innovative Technology (GHIT) Fund announced in November 2024 an investment of 4 million USD in four projects aimed at developing new drugs and diagnostics for NTDs and Malaria.
   

Middle East and Africa: The neglected tropical disease treatment market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• The market for neglected tropical diseases (NTDs) in Saudi Arabia is influenced by various factors, including climate conditions, migration patterns, and healthcare initiatives. Vector-borne illnesses such as leishmaniasis and dengue fever continue to be significant concerns, requiring focused control measures.
   
• The World Health Organization (WHO) reported that Saudi Arabia successfully eliminated trachoma as a public health issue in 2022, showing the nation's commitment to addressing NTDs through ongoing public health efforts.
   
• A study published in Springer showed that the estimated pooled prevalence of dengue fever in the country was 0.20 (95% CI: 0.05–0.53), highlighting the ongoing challenge of mosquito-borne diseases.
   
• Saudi Arabia is actively investing in better disease surveillance, vector control initiatives, and research partnerships to improve diagnostic capabilities and treatment access.
   
• With increasing healthcare spending and government-led programs, the NTD market in the nation is expected to grow, focusing on prevention strategies and new treatment solutions to reduce the disease burden.
   

Neglected Tropical Disease Treatment Market Share

The treatment market of neglected tropical disease (NTD) is one of the most advanced and competitive fields where large pharmaceutical firms and new biotech companies compete to gain higher market share. The top 4 players in this market are GlaxoSmithKline, Johnson & Johnson, Sanofi, and Merck, accounting for about 40% of market share. This is due to their extensive drug donation initiatives, regional presence, and product portfolios aimed at treating lymphatic filariasis, onchocerciasis, and sleeping sickness.
 

Important campaigns focus on creating new therapies, like targeted and combination drugs, to address the difficult aspects of NTDs and improve patient recovery results. Work is also being done to create vaccines, diagnostics like rapid test kits, and digital healthcare technologies, which allow better management of these NTDs and early detection. These strategies encourage cooperation with global health organizations, research groups, and government agencies to improve the region's drug development and market access.
 

Neglected Tropical Disease Treatment Market Companies

Some of the eminent market participants operating in the neglected tropical disease treatment industry include:

• Astellas Pharma
• Bayer
• Bharat Biotech
• Eisai
• Gilead Sciences
• GlaxoSmithKline
• Johnson & Johnson
• Merck
• Novartis
• Pfizer
• Sanofi
• Takeda Pharmaceutical
• Tarsus Pharmaceuticals
   
• Eisai is dedicated to corporate social responsibility through its drug donation programs for neglected tropical diseases (NTDs). The company provides Diethylcarbamazine (DEC) tablets at no cost to the World Health Organization (WHO) until lymphatic filariasis is eliminated. This program has helped millions of people in regions where the disease is common, especially in Asia and Africa, by reducing transmission rates and supporting efforts to eliminate the disease.
   
• GlaxoSmithKline (GSK) shows its global commitment to fighting neglected tropical diseases through partnerships and donations. Since 1998, the company has been providing albendazole tablets to help eliminate lymphatic filariasis. By 2023, GSK has donated more than 10 billion albendazole tablets to support WHO-led mass drug administration programs across 65 countries.
   

Neglected Tropical Disease Treatment Industry News:

• In September 2024, the World Health Organization (WHO) approved fexinidazole, which is an oral treatment for sleeping sickness (human African trypanosomiasis). This treatment will change the way the disease is treated for people living in the most remote areas of sub-Saharan Africa, as it was developed by Sanofi and does not need an intravenous drip and long hospital stays. The WHO approval will also help improve access and distribution efforts worldwide, which will help the people suffering from these diseases and improve their health outcomes.
   
• In October 2023, Drugs & Diagnostics for Tropical Diseases (DDTD), Big Eye Diagnostics (BEDx), and Medical & Biological Laboratories, Inc. (MBL) joined together to bring a rapid diagnostic test (RDT) for onchocerciasis to market. The test, developed by DDTD, meets WHO's requirements and received USD 0.45 million in funding from GHIT Fund. This test is expected to help control and eliminate the disease globally.
   

The neglected tropical disease treatment market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Disease Type

• Dengue
• Rabies
• Trachoma
• Buruli ulcer
• Yaws
• Leprosy
• Chagas disease
• Human African trypanosomiasis (sleeping sickness)
• Leishmaniases
• Soil-transmitted helminthiases
• Other disease types

Market, By Treatment Type

• Drugs
  • Anti-Parasite
  • Antifungal
  • Antibiotics
  • Other drugs
• Vaccines

Market, By Route of Administration

• Oral
• Injectable

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE